Adicet Bio Inc (ACET) - Total Assets
Based on the latest financial reports, Adicet Bio Inc (ACET) holds total assets worth $192.35 Million USD as of December 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See ACET net asset value for net asset value and shareholders' equity analysis.
Adicet Bio Inc - Total Assets Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's total assets have evolved over time, based on quarterly financial data.
Adicet Bio Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Adicet Bio Inc's total assets of $192.35 Million consist of 83.7% current assets and 16.3% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 20.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2008–2025)
This chart illustrates how Adicet Bio Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market value of Adicet Bio Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adicet Bio Inc's current assets represent 83.7% of total assets in 2025, a decrease from 94.3% in 2008.
- Cash Position: Cash and equivalents constituted 20.2% of total assets in 2025, down from 22.6% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 2.0% in 2008.
- Asset Diversification: The largest asset category is goodwill at 0.0% of total assets.
Adicet Bio Inc Competitors by Total Assets
Key competitors of Adicet Bio Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Adicet Bio Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.47 | 9.29 | 9.10 |
| Quick Ratio | 7.47 | 9.29 | 8.99 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $139.40 Million | $160.74 Million | $203.92 Million |
Adicet Bio Inc - Advanced Valuation Insights
This section examines the relationship between Adicet Bio Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.64 |
| Latest Market Cap to Assets Ratio | 0.36 |
| Asset Growth Rate (YoY) | -12.7% |
| Total Assets | $192.35 Million |
| Market Capitalization | $69.22 Million USD |
Valuation Analysis
Below Book Valuation: The market values Adicet Bio Inc's assets below their book value (0.36x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Adicet Bio Inc's assets decreased by 12.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adicet Bio Inc (2008–2025)
The table below shows the annual total assets of Adicet Bio Inc from 2008 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $192.35 Million | -12.65% |
| 2024-12-31 | $220.22 Million | +6.23% |
| 2023-12-31 | $207.29 Million | -37.31% |
| 2022-12-31 | $330.69 Million | -2.43% |
| 2021-12-31 | $338.94 Million | +120.33% |
| 2020-12-31 | $153.84 Million | +88.55% |
| 2019-12-31 | $81.59 Million | -25.79% |
| 2018-12-31 | $109.94 Million | +99.19% |
| 2017-12-31 | $55.19 Million | -89.79% |
| 2016-12-31 | $540.78 Million | +10.41% |
| 2015-12-31 | $489.77 Million | +4.66% |
| 2014-12-31 | $467.98 Million | +44.69% |
| 2013-12-31 | $323.43 Million | +8.07% |
| 2012-12-31 | $299.28 Million | +1.45% |
| 2011-12-31 | $294.99 Million | +36.22% |
| 2010-12-31 | $216.56 Million | +14.41% |
| 2009-12-31 | $189.27 Million | -7.90% |
| 2008-12-31 | $205.50 Million | -- |
About Adicet Bio Inc
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy express… Read more